Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal (Q38040848)

27 August 2017

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal (English)

1 reference

27 August 2017

0 references

1 reference

Kath Wright

6

0 references

author name string

Jane Burch

1

1 reference

27 August 2017

Susan Griffin

2

1 reference

27 August 2017

Claire McKenna

3

1 reference

27 August 2017

Simon Walker

4

1 reference

27 August 2017

James Paton

5

1 reference

27 August 2017

Nerys Woolacott

7

1 reference

27 August 2017

language of work or name

1 reference

1 November 2012

1 reference

27 August 2017

1 reference

27 August 2017

30

1 reference

27 August 2017

11

1 reference

27 August 2017

991-1004

1 reference

https://scigraph.springernature.com/pub.10.2165/11597160-000000000-00000

27 August 2017

0 references

cites work

Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally

1 reference

https://api.crossref.org/works/10.2165%2F11597160-000000000-00000

Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597160-000000000-00000

Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597160-000000000-00000

Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597160-000000000-00000

Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597160-000000000-00000

Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597160-000000000-00000

Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597160-000000000-00000

Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597160-000000000-00000

Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597160-000000000-00000

Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597160-000000000-00000

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597160-000000000-00000

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597160-000000000-00000

Factors associated with mortality after an asthma admission: a national United Kingdom database analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597160-000000000-00000

Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597160-000000000-00000

Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597160-000000000-00000

Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal

21 January 2018

1 reference

12 December 2020

Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal

1 reference

12 December 2020

Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal

1 reference

12 December 2020

Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal

1 reference

12 December 2020

Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal

1 reference

12 December 2020

The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK

1 reference

12 December 2020

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma

1 reference

12 December 2020

10.2165/11597160-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

0 references

1 reference